when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL · news · pharmadog

← back to BRISTOL

News mentioning BRISTOL

236 stories

Jul 23, 26Scancell to go public after winning reverse merger bid for troubled Neuphoriafiercebiotech

Jul 23, 26Biopharma layoffs must double in H2 for 2026 to match 2025 cutsbiospace

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 22, 26Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onbiospace

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 21, 26Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’biopharma dive

Jul 21, 26Is there an exodus underway at Epic?stat

Jul 21, 26Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsfiercebiotech

Jul 20, 26FDA still focused on lettuce supplier as source of parasite, despite faulty test resultstat

Jul 20, 26STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and morestat

Jul 20, 26Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharma dive

Jul 20, 26Bristol Myers, Nvidia say they'll build 'most powerful' AI supercomputer in pharmaendpoints

Jul 20, 26STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputerstat

Jul 20, 26BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’fiercebiotech

Jul 20, 26How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorbiospace

Jul 17, 26BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsfiercebiotech

Jul 16, 26Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunobiospace

Jul 16, 26Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updatefiercebiotech

Jul 16, 26Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialfiercebiotech

Jul 16, 26Opinion: The growing fang-to-pharmacy pipelinestat

Jul 15, 26Braveheart, Attovia join next wave of biotech IPOsbiopharma dive

Jul 13, 26Agenus surges on study pivot; Apnimed lines up an IPObiopharma dive

Jul 6, 26Bristol Myers details Krazati confirmatory study failure in colorectal cancerendpoints

Jul 2, 26A PureTech startup banks $180M for a new IPF drugbiopharma dive

Jul 2, 26Roche KRAS drug succeeds in head-to-head lung cancer studybiopharma dive

Jul 2, 26Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 studyendpoints

Jul 1, 26Abivax shares surge as worries subside over immune drug’s cancer riskbiopharma dive

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 30, 26Beeline ups its Series A round for immune drug workbiopharma dive

Jun 30, 26Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myersendpoints

← prevpage 6 of 8next →